A Phase 3 interventional study of LY2963016 and Lantus® in Type 2 Diabetes, sponsored by Eli Lilly and Company. Completed at 32 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-25.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 — 4 open to participants now, 6 under way, 1 of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 2.
Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, this one is the 39th largest by enrollment of the 175 interventional ones that give a count, is one of 7 that started in 2018, is one of 60 in phase 3, and was the 144th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Sanofi · Sites in China
Ages 18+
Loyola University · Sites in United States
Ages 18+ · Women only
Third Affiliated Hospital, Sun Yat-Sen University · Sites in China
Ages 30–65
Yanbing Li
Ages 18–70
By country, each count listing its studies:
Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
176 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 7 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 536 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 253 across the 175 interventional studies. Of the 161 that completed or were terminated, 56 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
122 of 176 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 55th largest by enrollment of the 232 interventional ones that give a count, is one of 8 that started in 2018, is one of 85 in phase 3, and was the 135th registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
1 of the studies testing Insulin Glargine in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare long-acting basal insulin analog LY2963016 to Lantus® in insulin naïve adult Chinese participants with Type 2 Diabetes Mellitus (T2DM) on 2 or more oral antihyperglycemic medications (OAMs). Participants will continue their OAMs throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Insulin naive participants started on 10 units (U) LY2963016 given subcutaneously (SC) once a day (QD) for 24 weeks. Participants-driven titration was supervised by investigators through the course of the study to maintain the fasting blood glucose (FBG) ≤100 milligram per deciliter (mg/dL) (5.6 millimoles per litre \[mmol/L\]) while avoiding hypoglycemia. Participants were allowed to continue oral antihyperglycemic medication (OAM).
Drug: LY2963016
Insulin naive participants started on 10 U Lantus® given SC QD for 24 weeks. Participants-driven titration was supervised by investigators through the course of the study to maintain the FBG ≤100 mg/dL (5.6 mmol/L) while avoiding hypoglycemia. Participants were allowed to continue oral OAM.
Drug: Lantus®
Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®)
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least square (LS) mean was calculated by mixed-effects model for repeated measures (MMRM) with baseline, insulin secretagogues at study entry, treatment, visit and treatment\*visit in the model.
Time frame: Baseline, Week 24
Change From Baseline in HbA1c (Lantus® to LY2963016)
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. LS mean was calculated by MMRM with baseline, insulin secretagogues at study entry, treatment, visit and treatment\*visit in the model.
Time frame: Baseline, Week 24
Change From Baseline in 7-Point Self-Monitored Blood Glucose (SMBG) Values
Seven-point SMBG are completed at the following timepoints: Before Morning Meal, 2 Hours After Morning Meal, Before Mid-Day Meal, 2 Hours After Mid-Day Meal, Before Evening Meal, 2 Hours After Evening Meal and Bed Time. LS mean was calculated by MMRM with baseline, insulin secretagogues at study entry, baseline HbA1c, treatment, time and treatment\*time in the model.
Time frame: Baseline, Week 24
Percentage of Participants With HbA1c <7% at Week 24
The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100.
Time frame: Week 24
Percentage of Participants With HbA1c ≤6.5% at Week 24
The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100.
Time frame: Week 24
Change From Baseline in Glycemic Variability of Fasting Blood Glucose
Glycemic variability is measured by the intra-participant standard deviation (SD) value of fasting blood glucose as measured by the actual morning and daily pre-meal blood glucose value from the 7-point self-monitoring blood glucose \[SMBG\] profiles. LS mean was calculated by MMRM with baseline, insulin secretagogues at study entry, baseline HbA1c, treatment, time and treatment\*time in the model.
Time frame: Baseline, Week 24
Basal Insulin Dose Units Per Day
Units of basal insulin dose taken per day (U/day). LS mean was calculated by MMRM with baseline, insulin secretagogues at study entry, baseline HbA1c, treatment, time and treatment\*time in the model.
Time frame: At Week 24
Change From Baseline in Basal Insulin Dose Units Per Day
Units of basal insulin dose taken per day (U/day). LS mean was calculated by MMRM with baseline, insulin secretagogues at study entry, baseline HbA1c, treatment, time and treatment\*time in the model.
Time frame: Baseline, Week 24
Change From Baseline in Body Weight
Change from baseline in body weight was evaluated. LS mean was calculated by MMRM with baseline, insulin secretagogues at study entry, baseline HbA1c, treatment, time and treatment\*time in the model.
Time frame: Baseline, Week 24
Insulin Treatment Satisfaction Questionnaire (ITSQ)
ITSQ is a validated instrument containing 22 items that assess treatment satisfaction for participants with diabetes and on insulin. Items divided into 5 domains of satisfaction: Inconvenience of Regimen \[(IR) 5 items: domain scores range (DSR) 5-35\], Lifestyle Flexibility \[(LF) 3 items: DSR 3-21\], Glycemic Control \[(GC) 3 items: DSR 3-21\], Hypoglycemic Control \[(HC) 5 items: DSR 5-35\], Insulin Delivery Device \[(IDD) 6 items: DSR 6-42\]. All items measured on a 7-point scale: 1 (no bother at all) to 7 (a tremendous bother), with lower scores reflecting better outcomes. ITSQ Total Overall Raw Scores range from 22-154. Both raw domain and overall scores are transformed on a scale of 0-100, where transformed score=100\*\[(7-mean raw score)/6\]. Higher scores indicate better treatment satisfaction. LS mean was calculated by MMRM with baseline, insulin secretagogues at study entry, baseline HbA1c, treatment, time and treatment\*time in the model.
Time frame: At Week 24
Number of Participants With Detectable Anti-Glargine Antibodies
Number of participants with detectable anti-glargine antibodies were reported.
Time frame: Baseline through 24 weeks
Rate of Total Symptomatic and Nocturnal Hypoglycemia Events (Adjusted by 1 Year)
Hypoglycemic episodes are defined as events that are associated with reported signs and symptoms of hypoglycemia and/or documented blood glucose (BG) concentrations of ≤70 mg/dL (3.9 mmol/L). The overall yearly rates (events/participant/year) of those hypoglycemic events, calculated as, for each participant, the number of episodes times 365.25 and then divided by the participants treatment duration, will be summarized, and analyzed by a negative-binomial regression model with treatment as fixed effects and log of (participant's treatment duration/365.25) as an offset variable. A nocturnal hypoglycemic event is defined as any total hypoglycemia event that occurred between bedtime and waking.
Time frame: Baseline through 24 weeks
| Milestone | LY2963016 | Lantus® |
|---|---|---|
| Started | 359 | 177 |
| Received at least one dose of study drug | 359 | 177 |
| Completed | 336 | 159 |
| Not completed | 23 | 18 |
| Withdrew: Withdrawal by subject | 14 | 8 |
| Withdrew: Lost to follow-up | 4 | 2 |
| Withdrew: Adverse event | 3 | 2 |
| Withdrew: Physician decision | 2 | 2 |
| Withdrew: Non-compliance with study drug | 0 | 3 |
| Withdrew: Protocol violation | 0 | 1 |
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least square (LS) mean was calculated by mixed-effects model for repeated measures (MMRM) with baseline, insulin secretagogues at study entry, treatment, visit and treatment\*visit in the model.
| Percentage of HbA1c | LY2963016 | Lantus® |
|---|---|---|
| Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) | -1.27 ± 0.043 | -1.23 ± 0.062 |
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. LS mean was calculated by MMRM with baseline, insulin secretagogues at study entry, treatment, visit and treatment\*visit in the model.
| Percentage of HbA1c | LY2963016 | Lantus® |
|---|---|---|
| Change From Baseline in HbA1c (Lantus® to LY2963016) | -1.27 ± 0.043 | -1.23 ± 0.062 |
Seven-point SMBG are completed at the following timepoints: Before Morning Meal, 2 Hours After Morning Meal, Before Mid-Day Meal, 2 Hours After Mid-Day Meal, Before Evening Meal, 2 Hours After Evening Meal and Bed Time. LS mean was calculated by MMRM with baseline, insulin secretagogues at study entry, baseline HbA1c, treatment, time and treatment\*time in the model.
| milligrams per deciliter (mg/dL) | LY2963016 | Lantus® |
|---|---|---|
| Before Morning Meal Glucose | -48.7 ± 1.09 | -49.7 ± 1.59 |
| 2 Hours After Morning Meal Glucose | -56.3 ± 2.34 | -52.7 ± 3.39 |
| Before Mid-Day Meal Glucose | -43.2 ± 2.03 | -39.9 ± 2.93 |
| 2 Hours After Mid-Day Meal Glucose | -31.0 ± 2.31 | -35.9 ± 3.33 |
| Before Evening Meal Glucose | -32.1 ± 2.21 | -33.0 ± 3.19 |
| 2 Hours After Evening Meal Glucose | -29.7 ± 2.46 | -32.0 ± 3.55 |
| Bedtime Glucose | -31.6 ± 2.35 | -33.0 ± 3.40 |
The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100.
| Percentage of participants | LY2963016 | Lantus® |
|---|---|---|
| Percentage of Participants With HbA1c <7% at Week 24 | 43.7 | 44.9 |
The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100.
| Percentage of participants | LY2963016 | Lantus® |
|---|---|---|
| Percentage of Participants With HbA1c ≤6.5% at Week 24 | 23.4 | 16.5 |
Glycemic variability is measured by the intra-participant standard deviation (SD) value of fasting blood glucose as measured by the actual morning and daily pre-meal blood glucose value from the 7-point self-monitoring blood glucose \[SMBG\] profiles. LS mean was calculated by MMRM with baseline, insulin secretagogues at study entry, baseline HbA1c, treatment, time and treatment\*time in the model.
| milligrams per deciliter (mg/dL) | LY2963016 | Lantus® |
|---|---|---|
| Morning Pre-meal Standard Deviation | -2.17 ± 0.606 | -2.49 ± 0.879 |
| Daily Mean Standard Deviation | -4.1 ± 0.85 | -4.5 ± 1.22 |
Units of basal insulin dose taken per day (U/day). LS mean was calculated by MMRM with baseline, insulin secretagogues at study entry, baseline HbA1c, treatment, time and treatment\*time in the model.
| units per day (U/day) | LY2963016 | Lantus® |
|---|---|---|
| Basal Insulin Dose Units Per Day | 16.0 ± 0.43 | 15.7 ± 0.61 |
Units of basal insulin dose taken per day (U/day). LS mean was calculated by MMRM with baseline, insulin secretagogues at study entry, baseline HbA1c, treatment, time and treatment\*time in the model.
| U/day | LY2963016 | Lantus® |
|---|---|---|
| Change From Baseline in Basal Insulin Dose Units Per Day | 7.0 ± 0.43 | 6.8 ± 0.61 |
Change from baseline in body weight was evaluated. LS mean was calculated by MMRM with baseline, insulin secretagogues at study entry, baseline HbA1c, treatment, time and treatment\*time in the model.
| kilogram (kg) | LY2963016 | Lantus® |
|---|---|---|
| Change From Baseline in Body Weight | 1.1 ± 0.13 | 1.2 ± 0.19 |
ITSQ is a validated instrument containing 22 items that assess treatment satisfaction for participants with diabetes and on insulin. Items divided into 5 domains of satisfaction: Inconvenience of Regimen \[(IR) 5 items: domain scores range (DSR) 5-35\], Lifestyle Flexibility \[(LF) 3 items: DSR 3-21\], Glycemic Control \[(GC) 3 items: DSR 3-21\], Hypoglycemic Control \[(HC) 5 items: DSR 5-35\], Insulin Delivery Device \[(IDD) 6 items: DSR 6-42\]. All items measured on a 7-point scale: 1 (no bother at all) to 7 (a tremendous bother), with lower scores reflecting better outcomes. ITSQ Total Overall Raw Scores range from 22-154. Both raw domain and overall scores are transformed on a scale of 0-100, where transformed score=100\*\[(7-mean raw score)/6\]. Higher scores indicate better treatment satisfaction. LS mean was calculated by MMRM with baseline, insulin secretagogues at study entry, baseline HbA1c, treatment, time and treatment\*time in the model.
| units on a scale | LY2963016 | Lantus® |
|---|---|---|
| IR | 89.36 ± 0.80 | 90.31 ± 1.16 |
| LF | 83.70 ± 1.05 | 87.69 ± 1.52 |
| HC | 89.07 ± 0.79 | 90.86 ± 1.15 |
| GC | 87.80 ± 0.84 | 87.83 ± 1.21 |
| IDD | 86.84 ± 0.86 | 88.29 ± 1.24 |
| ITSQ Overall Total | 87.32 ± 0.75 | 88.99 ± 1.08 |
Number of participants with detectable anti-glargine antibodies were reported.
| participants | LY2963016 | Lantus® |
|---|---|---|
| Number of Participants With Detectable Anti-Glargine Antibodies | 69 | 31 |
Hypoglycemic episodes are defined as events that are associated with reported signs and symptoms of hypoglycemia and/or documented blood glucose (BG) concentrations of ≤70 mg/dL (3.9 mmol/L). The overall yearly rates (events/participant/year) of those hypoglycemic events, calculated as, for each participant, the number of episodes times 365.25 and then divided by the participants treatment duration, will be summarized, and analyzed by a negative-binomial regression model with treatment as fixed effects and log of (participant's treatment duration/365.25) as an offset variable. A nocturnal hypoglycemic event is defined as any total hypoglycemia event that occurred between bedtime and waking.
| events/participant/year | LY2963016 | Lantus® |
|---|---|---|
| Total hypoglycemia | 1.37 ± 0.228 | 1.15 ± 0.280 |
| Nocturnal Hypoglycemia | 0.47 ± 0.132 | 0.39 ± 0.110 |
Collected over Baseline Up To 28 Weeks. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LY2963016 | 0/359 (0%) | 28/359 (7.8%) | 194/359 (54%) |
| Lantus® | 0/177 (0%) | 14/177 (7.9%) | 95/177 (53.7%) |
| Event | LY2963016 | Lantus® |
|---|---|---|
| Cerebral infarctionNervous system disorders | 5/359 | 2/177 |
| PneumoniaInfections and infestations | 3/359 | 1/177 |
| AnaemiaBlood and lymphatic system disorders | 0/359 | 1/177 |
| Cardiac failure congestiveCardiac disorders | 0/359 | 1/177 |
| Coronary artery diseaseCardiac disorders | 1/359 | 1/177 |
| ColitisGastrointestinal disorders | 0/359 | 1/177 |
| Gastrointestinal polypGastrointestinal disorders | 0/359 | 1/177 |
| Large intestine polypGastrointestinal disorders | 1/359 | 1/177 |
| Hepatitis eInfections and infestations | 0/359 | 1/177 |
| Soft tissue infectionInfections and infestations | 1/359 | 1/177 |
| Event | LY2963016 | Lantus® |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 73/359 | 32/177 |
| Weight increasedInvestigations | 14/359 | 11/177 |
| HypertensionVascular disorders | 20/359 | 7/177 |
| Injection site painGeneral disorders | 15/359 | 5/177 |
| NasopharyngitisInfections and infestations | 8/359 | 7/177 |
| CoughRespiratory, thoracic and mediastinal disorders | 13/359 | 5/177 |
| BronchitisInfections and infestations | 3/359 | 6/177 |
| Diabetic neuropathyNervous system disorders | 1/359 | 5/177 |
| DiarrhoeaGastrointestinal disorders | 10/359 | 4/177 |
| ToothacheGastrointestinal disorders | 9/359 | 1/177 |
All randomized participants who received at least one dose of study drug.
| Age, Continuous(years) | LY2963016 | Lantus® | Total |
|---|---|---|---|
| Mean | 58.3 ± 9.6 | 59.5 ± 8.9 | 58.7 ± 9.4 |
| Sex: Female, Male(Participants) | LY2963016 | Lantus® | Total |
|---|---|---|---|
| Female | 150 | 79 | 229 |
| Male | 209 | 98 | 307 |
| Race (NIH/OMB)(Participants) | LY2963016 | Lantus® | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 359 | 177 | 536 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | LY2963016 | Lantus® | Total |
|---|---|---|---|
| China | 359 | 177 | 536 |
| Baseline Hemoglobin A1c (HbA1c)(Percentage of HbA1c) | LY2963016 | Lantus® | Total |
|---|---|---|---|
| Mean | 8.42 ± 1.04 | 8.39 ± 0.92 | 8.41 ± 1.00 |
| Duration of Diabetes(years) | LY2963016 | Lantus® | Total |
|---|---|---|---|
| Mean | 10.09 ± 5.47 | 10.69 ± 5.94 | 10.29 ± 5.63 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Mar 2018 to primary completion in Mar 2020, 23 months.
Results were first posted in May 2021, 1 year 2 months after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 23 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin Glargine